Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Am Chem Soc. Author manuscript; available in PMC 2013 April 11.
Published in final edited form as:
PMCID: PMC3324671

In cell fluorescence activation and labeling of proteins mediated by FRET-quenched split inteins


Methods to visualize, track and modify proteins in living cells are central for understanding the spatial and temporal underpinnings of life inside cells. Although fluorescent proteins have proven to be extremely useful for in vivo studies of protein function, their utility is inherently limited because their spectral and structural characteristics are interdependent. These limitations have spurred the creation of alternative approaches for the chemical labeling of proteins. We report in this work the use of fluorescence resonance emission transfer (FRET)-quenched DnaE split-inteins for the site-specific labeling and concomitant fluorescence activation of proteins in living cells. We have successfully employed this approach for the site-specific in-cell labeling of the DNA binding domain (DBD) of the transcription factor YY1 using several human cell lines. Moreover, we have shown that this approach can be also used for modifying proteins in order to control their cellular localization and potentially alter their biological activity.


Elucidating the distribution, dynamics and chemical environment of proteins inside living cells is critical for understanding the biomolecular mechanisms of cellular function.1-3 Labeling of proteins with fluorescent probes or affinity reagents has facilitated in vitro studies of protein structure, dynamics and protein–protein interactions.4 However, traditional methods of protein labeling are often inadequate for in vivo studies because they require purification of the protein, chemical labeling, repurification and reintroduction into cells by invasive methods such as microinjection. These limitations have spawned efforts to non-invasively and site-specifically label proteins in living cells or tissue.

The most prominent method of protein labeling is to genetically encode green fluorescent protein (GFP) or one of its variants as a fusion to the protein of interest.5,6 Although GFP variants have proven to be extremely useful for in vivo studies of protein function, their utility is somehow inherently limited because their relatively large sizes, potential for oligomerization and sometimes slow or incomplete maturation times.

This need for chemically diverse protein labels has led researchers to develop novel ways to label fusion proteins with small molecular probes and/or quantum dots (QDs).3,7,8 Most of the approaches developed so far for the chemical labeling of proteins in vivo exploit specific, high-affinity non-covalent or covalent interactions between a synthetic ligand and its corresponding receptor. These include hapten–antibody,9 biotin–avidin,10 various enzyme–inhibitor combinations,11-14 nitrilotriacetate (NTA)-oligohistidine sequence,15 different chemoselective reactions16 and Cys-rich peptides that bind biarsenical fluorophores17 and QDs.18 Most of these approaches, however, show limited applicability for the simultaneous incorporation of multiple fluorescent tags as well as limited temporal/spatial control for the in vivo labeling process.

One of the most promising approaches for in vivo protein labeling involves the use of intein-mediated protein trans-splicing.19 Intein-mediated labeling of proteins is highly modular allowing the covalent site-specific incorporation of a myriad of biophysical probes into proteins.20-22 The kinetics of protein splicing is also relatively fast, with a number of split-inteins having reaction times in the order of several minutes.21,23,24 Moreover, the recent development of conditional protein splicing, both through chemical and photochemical means, makes possible the chemical modification of proteins in living cells with temporal and spatial control.25-28 The use of protein trans-splicing for the site-specific labeling of proteins with fluorogenic dyes for in vivo tracking purposes, however, requires that the labeling process must be linked to the simultaneous activation of fluorescence. This is key to the supression cellular background fluorescence due to the presence of the unreacted intein-fragment (Figure 1). In this work, we report the use of fluorescence resonance emission transfer (FRET)-quenched DnaE split-inteins for the site-specific labeling and concomitant fluorescence activation of proteins in living cells. We have successfully used this approach for the site-specific in-cell labeling of the DNA binding domain (DBD) of the transcription factor YY1 using several human cell lines. We have also shown that this approach can be easily employed to modify proteins to control their cellular localization and potential biological function.

Figure 1
A. Site-specific labeling and fluorescence activation of a protein of interest (POI) by FRET-quenched protein trans-splicing. Key to this approach is the introduction of fluorescence quencher into the IC polypeptide, which blocks the fluorescence signal ...

Results and Discussion

Design and synthesis of FRET-quenched DnaE split inteins

Intein-mediated protein trans-splicing has been used in a multitude of applications including protein backbone cyclization,29-32 protein immobilization,21,33-35 protein semi-synthesis,36 and segmental isotopic labeling,37-40 among others. Of particular interest is the use of protein trans-splicing for in vivo site-specific functionalization of proteins.25-27,41,42 For example, the introduction of biophysical probes such as organic or inorganic fluorescent probes could allow the derivatization of proteins for optical tracking purposes in living cells. In order to be successful, however, it is key that the fluorescence should only be activated once the trans-splicing reaction has occurred. This will eliminate any detrimental fluorescence background coming from the corresponding unreacted split-intein precursor therefore facilitating the optical tracking of the labeled protein (Fig. 1).

In protein trans-splicing, the intein self-processing domain is split in two fragments, called N-intein (IN) and C-intein (IC), respectively. These two intein fragments do not have any protein splicing activity individually. However, they can bind each other with high specificity to produce a fully functional protein-splicing domain able to ligate the N- and C-extein segments through a native peptide bond (Fig. 1). One of the best-characterized naturally occurring split-inteins is the Syncechocystis sp. strain PCC6803 (Ssp) α-subunit DNA polymerase III (DnaE) intein,43 which has many known orthologs with high sequence homology in other cyanobacteria species23,44 (Fig. 2C). In the Ssp DnaE intein the IN and IC fragments have 123 and 36 residues, respectively. The relatively small size of the IC fragment facilitates its chemical synthesis thus allowing the use of synthetic IC fragments bearing different biophysical probes in the C-extein segment to be used for the chemical modification of proteins through protein trans-splicing.21,26,27

Figure 2
Design of FRET-quenched DnaE split inteins. A. Crystal structure of the Ssp DnaE intein in the pre-spliced state (PDB code: 1ZDE).46 DnaE IC and IN are shown in red and blue respectively. The structural secondary elements are also shown. The positions ...

We hypothesized that the chemical introduction of a fluorescence quencher on specific locations of the IC polypeptide could quench, in a reversible fashion the fluorescence of a suitable fluorogenic probe located in the C-extein fragment thus rendering any unreacted IC virtually non-fluorescent. Hence only after the trans-splicing reaction has occurred and the C-extein fragment has been transferred to the acceptor protein, the fluorescence of the probe would be activated resulting in the concomitant fluorescence activation and labeling of the protein of interest (Fig. 1).

To test this hypothesis we initially used the well-characterized Ssp DnaE split-intein43 in combination with fluorescein and dabcyl as fluorescence donor and FRET-quencher, respectively (Fig. 2). The fluorescein group was introduced at the C-terminus of the first four residues (Cys-Phe-Asn-Lys) of the C-extein, which are required for efficient trans-splicing.21,27,45 The dabcyl group was first introduced at the N-terminus of the IC polypeptide (QN, Fig. 2).

Modification of the N-terminus of the Ssp DnaE IC intein has been shown not to affect the splicing activity of this split-intein.21,24,27 According to the crystal structure of the Ssp DnaE split intein,46 the distance between the fluorophore and the quencher in this case (peptide 3, Table 1) was estimated to be ≈30 Å (Fig. 2A), well in-range for efficient FRET-quenching. In addition, we also explored introducing the dabcyl group (QM, Fig. 2) on residue 22 of the Ssp DnaE IC polypeptide (peptide 4, Table 1). This position is in closer proximity to the C-extein both in the sequence and in the structure of the split intein complex (≈17 Å, Fig. 2A) and in principle should provide better FRET-quenching than the N-terminal position (peptide 3). Also, position 22 is not well conserved among other cyanobacterial DnaE IC split inteins (Fig. 2C) suggesting that is not essential for trans-splicing and that the original Gln residue in this position could be replaced by Lys(Nε-dabcyl) with minimal impact of the splicing ability of the modified IC polypeptide (peptide 4). We also used this position to prepare a FRET-quenched version of the Nostoc puntiforme PCC73102 (Npu) DnaE IC intein (peptide 6), a highly homologous cyanobacterial DnaE intein (Figs. 2B and 2C).47,48 This DnaE intein has also be shown to have the highest rate reported for protein trans-splicing (τ1/2 ≈ 60 s)24 and a high splicing yield;24,47 and therefore is a good candidate for the use of protein trans-splicing for in cell molecular imaging and tracking purposes.

Table 1
Sequence of the different DnaE C-intein (IC) polypeptides used in this work. Standard single code letters are used for the peptides sequences. Single letter codes B and X stand for norleucine and 6-amino hexanoic acid, respectively. Fluorescein isothiocyanate ...

Accordingly, we synthesized peptides 3, 4 and 7 (Table 1) using Fmoc-based solid-phase peptide synthesis (SPPS) as depicted in Fig. 3. Once the synthesis of peptide 3 was completed, the Nα-Fmoc group was deprotected with piperidine and the resulting amino group acylated with dabcyl. Fluorescein was then introduced at the C-terminus of the first four residues of the C-extein through the e-amino group of a Lys(Dde) residue (Fig. 3A and Table 1). This was accomplished by first using hydrazine to remove the Dde group and then acylating the resulting ε-amino group with fluorescein isothiocyanate (FITC). In the case of peptides 4 and 7, the fluorescein group was introduced first through the thiol group of a Cys(S-tBu) located at the C-terminus of the first four residues of the C-extein (Fig. 3B and Table 1). After removal of the S-tBu group by treatment with β-mercaptoethanol, the thiol group was alkylated with 5-iodoacetamido fluorescein (5-IAF). The dabcyl group was then introduced on position 22 through the ε-amino group of a Lys(Dde) residue. The Dde protecting group was deprotected as above with hydrazine and acylated with dabcyl.

Figure 3
Synthetic approach used for the synthesis of FRET-quenched DnaE IC polypeptides. All peptides were synthesized by solid-phase peptide synthesis using Fmoc-based chemistry.

The Ssp and Npu wild-type DnaE IC inteins (peptides 1, 2, 5, and 6) with and without fluorescein at the C-terminus of the C-extein were also synthesized by Fmoc-SPPS as controls. In all the cases the final cleavage and deprotection of the polypeptides was achieved by treatment with TFA. The peptides were purified and characterized by HPLC and ES-MS (Table 1 and Fig. S1).

In vitro FRET-quenching of fluorescein,dabcyl-labeled DnaE IC polypeptides

First, we estimated the level of fluorescein quenching provided by the dabcyl group at the N-terminus and residue 22 of the Ssp DnaE IC intein. The dabcyl group was able to efficiently quench the fluorescence of the fluorescein moiety located at the C-extein of the intein in both constructs (Table 1). As anticipated, the fluorescence quenching was slightly more effective when the dabcyl group was located at residue 22 of the DnaE IC polypeptide (≈99%) than when it was placed at the N-terminus (≈93%). These results are in good agreement with the distances estimated between the fluorescein and dabcyl groups using the crystal structure of the Ssp DnaE inteins (Fig. 2A).46,48 A similar quenching efficiency (≈99%) was also observed for the FRET-quenched Npu DnaE IC intein (Table 1, peptide 7), which is in agreement with the high level of sequence and structural homology between these cyanobacterial split-inteins (Fig. 2B).

In vitro trans-splicing activities of modified DnaE IC polypeptides

Next, we evaluated the effect of the position of the dabcyl group on the trans-splicing activity of the different modified DnaE IC polypeptides (Table 1). We used the maltose binding protein (MBP) fused to the N-terminus of the Ssp (MBP-Ssp-IN) or Npu DnaE IN (MBP-Npu-IN) inteins as a model protein. The first four residues of the N-extein were also included to facilitate protein trans-splicing.21,45 The trans-splicing reactions were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) using the corresponding unmodified and fluorescein-labeled IC polypeptides as controls. As expected, the introduction of the dabcycl group on the N-terminal position of the Ssp DnaE intein had no effect on its trans-splicing activity (Figs. S4). The modification of the N-terminus of different IC peptides has been shown not to affect the activity or assembly of the DnaE split-intein.21,24,27 Intriguingly, modification of residue 22 to introduce the fluorescence quencher group had also a minimal effect on the splicing activity of both DnaE split-inteins (Fig. 4A). In both cases the trans-splicing yields were similar to those of the corresponding unmodified IC polypeptides (≈80%). Analysis by HPLC and mass spectrometry of the different trans-splicing reactions also confirmed the identity of the trans-spliced product as the C-terminal labeled MPB (Fig. S5). It is interesting to note that under the conditions used in this work no N-cleavage by-product (i.e. MBP) was detected in the trans-splicing reaction (Fig. S5).

Figure 4
In vitro protein trans-splicing using FRET-quenched DnaE split inteins. A. SDS-PAGE analysis of the trans-splicing reaction using FRET-quenched IC polypeptides. Protein detection was performed either by silver staining (top) or epifluorescence (bottom). ...

The kinetic analysis of the DnaE IC polypeptides derivatized with the dabcycl group on residue 22 also confirmed that the resulting FRET-quenched IC inteins had similar trans-splicing rates to those of the corresponding unmodified IC inteins (Fig. 4B). Hence, while peptide 4 (Ssp QM-IC-Fl) showed a slightly slower trans-splicing rate than the wild-type IC polypeptides (τ1/2 = 87 ± 20 min versus τ1/2 = 70 ± 10 min for the unmodified IC peptides, Fig. 4B), the Npu version of this peptide (7) showed identical kinetics to that of the wild-type peptides 5 and 6, with half-life times around 1 minute (Fig. 4B). The Npu DnaE intein is one of the fastest inteins reported so far, and the half-life values found in this work are in agreement with those previously reported.24,47

In summary, our data clearly shows that modification of residue 22 of the DnaE IC polypeptide to introduce a fluorescence quencher provides both good quenching yields (≈99%) and at the same time has a minimal (Ssp DnaE intein) or negligible (Npu DnaE) impact on the trans-splicing activity of the corresponding modified IC inteins. These results, combined with the fast kinetics of the Npu DnaE intein, make the modified Npu QM-IC-Fl polypeptide (7) the ideal choice to perform in-cell fluorescence activation and labeling of proteins by protein trans-splicing using FRET-quenched split inteins (Fig. 1).

In-cell trans-splicing activity of the FRET-quenched Npu QM-IC-Fl polypeptide (7)

We tested the splicing activity of peptide 7 (Npu QM-IC-Fl) in cells to evaluate its ability to label proteins with concomitant fluorescence activation. For this purpose we used the DNA binding domain (DBD) of the transcription factor Yin Yang 1 (YY1). YY1 is a ubiquitously distributed multifunctional transcription factor belonging to the GLI-Kruppel class of zinc finger proteins 49. The protein is involved in repressing and activating a diverse number of promoters including negative regulation of p53, thus making it of particular interest.50,51

First, the DBD of YY1 was fused to the N-terminus of the Npu DnaE IN intein (YY1-Npu-IN) and recombinantly expressed to test the splicing activity with the Npu IC intein 5 in vitro. The trans-splicing reaction was monitored by SDS-PAGE at different times and the proteins visualized by silver staining and epifluorescence to evaluate the kinetics and yield of the reaction (Fig. 5A). The splicing reaction was relatively efficient with a yield ≈32% and extremely fast with a half-life that was estimated ≈1 min (Fig. 5B). The identity of the trans-spliced product was also confirmed by mass spectrometry as the C-terminal labeled DBD of YY1 (Fig. 5C). Under these conditions, we were not able to detect any trace of N-cleavage product on the band corresponding to the trans-spliced product.

Figure 5
In vitro protein trans-splicing reaction between Npu DnaE IC and YY1-IN. Trans-splicing reactions between Npu DnaE IC (6) and YY1-Npu-IN constructs at 1 μM and 0.1 μM, respectively, were performed in splicing buffer (0.5 mM EDTA, 1 mM ...

For in-cell trans-splicing the protein YY1-Npu-IN was cloned into a mammalian expression vector and transiently expressed in mammalian cells for 24 h. We demonstrated the generality of this approach by using two different mammalian cell lines, U2OS and HeLa cells. Transient expression of YY1-Npu-IN was checked in both cell lines by western blotting reaching an intracellular concentration of ≈2 μM after 24 h expression as estimated by western blot (Fig. S6). The cells were then transfected with peptide 7 (Npu QM-IC-Fl) using the commercially available Chariot™ protein delivery reagent.52 This system uses the amphipathic peptide Pep-1,53 which has been shown to be able to deliver cargo polypeptides into several cell lines without the need for covalent coupling.53,54 Peptides 5 (Npu Ac-IC) and 6 (Npu Ac-IC-Fl) were also used as controls. Peptide transfection was carried out for 30 min with final peptide concentrations ranging from 10 to 50 nM in all the cases. The best peptide transfection efficiency was obtained for 50 nM IC using a molecular ratio IC:Pep-1 of 1:20 (Fig. S7). This ratio has been previously described as optimal when using Pep-1.53 Under these transfection conditions no cellular cytotoxicity was detected and the amount of peptide transfected into the cell was relatively constant reaching intracellular concentrations of ≈20 μM as estimated by SDS-PAGE (Fig. S8). Importantly, the transfection of fluorescent peptide 6 (Npu Ac-IC-Fl) was able to provide a strong fluorescent signal to the cells while the FRET-quenched intein peptide 7 was basically non-fluorescent when internalized into cells not expressing the IN intein fragment (Fig. S7). These results confirm the stability of the IC polypeptides to the intracellular conditions and the efficiency of the FRET-quenched intein to suppress the fluorescence of the fluorescein moiety in the absence of protein trans-splicing.

The in-cell trans-splicing reaction in HeLa and U2OS cells was monitored by fluorescence microscopy and SDS-PAGE (Fig. 6). After 2 h, the cells transfected with the FRET-quenched IC intein 7 and expressing YY1-Npu-IN already showed a significant amount of fluorescence (Fig. 6A). In-cell reactions longer than 2 h did not significantly increase the level of fluorescence, suggesting that the trans-splicing reaction is essentially completed in 2 h (Fig. 6A). This 2 h time period includes the peptide transfection (30 min) plus cell recovery (90 min). Time optimization of these processes should allow reducing the time required for the in-cell labeling reaction. As expected, the cells transfected only with FRET-quenched IC intein 7 remained basically non-fluorescent even after 18 h of incubation (Fig. 6A). This indicates the requirement of the IN intein to trigger trans-splicing and activation of fluorescence. Intriguingly, this also highlights the relative high stability of the IC polypeptide to intracellular degradation. Although we do not have a complete explanation for this unexpected result, it is worth noting that DnaE IC polypeptides have been described to have tendency to aggregate in vitro under physiological conditions in absence of the IN polypeptide.21,27 This process could explain the extra intracellular stability of the IC fragment, however, further studies will be required to fully elucidate the mechanism of such phenomenon. Quantification of the cellular fluorescence signal in cells transfected with YY1-Npu-IN revealed a ≈30-fold increase of fluorescence in both U2OS and HeLa cells when compared to cells transfected only with the FRET-quenched IC intein 7.

Figure 6
In-cell trans-splicing reaction using a FRET-quenched Npu DnaE split intein. A. HeLa or U2OS cells were first transiently transfected with a plasmid encoding YY1-Npu-IN. After 24 h of protein expression the cells were transfected with different fluorescent-labeled ...

Analysis by SDS-PAGE using western blot and epifluorescence of in-cell trans-splicing also verified the labeling of the protein YY1 and confirmed that the trans-splicing reaction was finished (≈20% yield) after 2 h incubation for both cell lines (Figs. 6B and S9). The identity of the in-cell trans-spliced product was further confirmed by LC/MS/MS (Fig. S10). In agreement with the fluorescence results, longer reaction times did not increase the amount of labeled protein (Fig. S9). This indicates a good correlation between the level of fluorescence detected in the live cells and the percentage of protein labeled. The in-cell protein trans-splicing yield (≈20%) is only slightly smaller than that when the reaction is performed in vitro (≈32%). This difference could be attributed to the more oxidative environment of the eukaryotic cellular cytosol.

In-cell modification of protein localization with concomitant fluorescence activation

Encouraged by these results, we tested this approach to see if it could also be used to modify the intracellular location of a protein with concomitant fluorescence activation to allow optical tracking inside a living cell. We introduced a nuclear localization signal (NLS) and a fluorescent label moiety at the C-terminus of DBD YY1. The DBD of YY1 lacks the original nuclear localization signal found in full length YY1 and therefore when expressed in mammalian cells is mostly distributed in the cytosol (Fig. 6). Thus the simultaneous introduction of a NLS and a fluorescent label into the C-terminus of DBD YY1 should allow the localization and visual tracking of the resulting protein into the nucleus.

We synthesized a FRET-quenched Npu IC intein incorporating a SV40 nuclear localization signal55 and a fluorescein moiety at the C-terminus of the C-extein (peptide 9) (Npu QM-IC-NLS-Fl, see Table 1). We also used a non-quenched fluorescein-labeled version of the same peptide (8) (Npu Ac-IC-NLS-Fl, see Table 1) as control. Both peptides were synthesized by Fmoc-based SPPS as described earlier (Fig. 3). Peptides 8 and 9 were internalized very efficiently in cells using the Chariot™ protein delivery reagent as described earlier (Figs. S7 and S8). As expected, the IC polypeptides containing the NLS sequence were localized mainly in the nucleus and perinuclear region of the cell (Figs. S7 and S11). In contrast IC peptide 6, which lacks the NLS sequence, showed mostly a cytosolic distribution (Fig. S11). In-cell trans-splicing reactions with NLS-containing IC polypeptides were also performed in U2OS and HeLa cells and monitored by fluorescence microscopy as described before. As shown in Figure 7, the cells transfected with the FRET-quenched IC polypeptide 9 and expressing YY1-Npu-IN increased their level of fluorescence after 2 h. In agreement with the previous results, when the same peptide was transfected into cells not expressing the IN intein construct, the cells remained non-fluorescent (Fig. 7A). The in-cell trans-splicing reaction was also complete after 2 h, and increasing the reaction time to 18 h did not raise the level of fluorescence signal (Fig. 7) or the labeling efficiency (≈20%, Fig. S9). More importantly, the fluorescence signal in cells transfected with the FRET-quenched IC polypeptide 9 and expressing YY1-Npu-IN accumulated in the nucleus and perinuclear regions (Fig. 7). This effect was more pronounced after 18 h, indicating a steady-state between the nuclear import and the diffusion-driven export of the labeled protein. Quantification of the fluorescence signal in these cells also showed a 30-fold increase over the fluorescence found in cells transfected with only with FRET-quenched IC intein 9 in the absence of protein YY1-Npu-IN (Fig. 7).

Figure 7
In-cell site-specific labeling of YY1 DBD with a nuclear localization signal and concomitant fluorescence activation using protein trans-splicing. A. HeLa or U2OS cells were first transiently transfected with a plasmid encoding YY1-Npu-IN and with different ...


In summary, we have described a new approach for the fast and efficient modification and simultaneous fluorescence labeling of proteins inside living cells using FRET-quenched protein trans-splicing. This new strategy allows the use of protein trans-splicing for the site-specific labeling of proteins with fluorophores and at the same time suppresses the background fluorescence from unreacted IC polypeptide. This is key for in vivo tracking purposes. We have shown that this approach is general and can be used for the site-specific modification of proteins to alter its cellular localization with concomitant fluorescent activation. As shown in this work, FRET-quenched IC polypeptides containing small or medium-sized fluorescent-labeled C-exteins can be easily accessed chemically through SPPS. IC polypeptides containing longer C-extein fragments could be also readily obtained through semi-synthesis by ligation of the quenched-labeled IC peptide thioester to a recombinantly obtained fluorescent-modified C-extein through native chemical ligation.56,57 Site-specific labeling of recombinant fragments can be accomplished using standard intein expression vectors.57 Hence, the use of this technique in combination with synthetic or semi-synthetic FRET-quenched IC polypeptides should allow the modification of proteins without limit on the size of the polypeptide fragments to be introduced. This could range from small regulatory peptide sequences, such as a NLS sequence shown in this study, to larger protein domains required for the full biological activity of the resulting protein.

This approach could also be readily adapted to other naturally or artificially-split inteins.58 The use of different orthogonal split inteins should in principle allow the simultaneous labeling of proteins with different fluorescent probes inside living cells for in-cell multicolor optical tracking. Moreover, the recent development of photomodulated protein trans-splicing26-28 should make feasible the use of photocaged FRET-quenched inteins in vivo with spatial and temporal control through highly focused and coherent light sources which should allow simultaneous in vivo tracking of the modified proteins.

Supplementary Material



This work was supported by National Institutes of Health Research Grant R01-GM090323 (JAC) and by the Department of Defense Congressionally Directed Medical Research Program Grant PC09305 (JAC).


Supporting Information: Experimental details, synthesis, purification and characterization of IC peptides, cloning expression and purification of IN proteins, in vitro and in vivo protein splicing protocols, fluorescence spectroscopy and microscopy, cell culture. This material is available free of charge via the Internet at


1. Xie XS, Yu J, Yang WY. Science. 2006;312:228–30. [PubMed]
2. Chen I, Ting AY. Curr Opin Biotechnol. 2005;16:35–40. [PubMed]
3. Miller LW, Cornish VW. Curr Opin Chem Biol. 2005;9:56–61. [PubMed]
4. Rao J, Dragulescu-Andrasi A, Yao H. Curr Opin Biotechnol. 2007;18:17–25. [PubMed]
5. Griffin BA, Adams SR, Tsien RY. Science. 1998;281:269–72. [PubMed]
6. Zhang J, Campbell RE, Ting AY, Tsien RY. Nat Rev Mol Cell Biol. 2002;3:906–18. [PubMed]
7. Marks KM, Nolan GP. Nat Methods. 2006;3:591–6. [PubMed]
8. Johnsson N, Johnsson K. ACS Chem Biol. 2007;2:31–8. [PubMed]
9. Farinas J, Verkman AS. J Biol Chem. 1999;274:7603–6. [PubMed]
10. Howarth M, Takao K, Hayashi Y, Ting AY. Proc Natl Acad Sci U S A. 2005;102:7583–8. [PubMed]
11. Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, Zimprich C, Wood MG, Learish R, Ohana RF, Urh M, Simpson D, Mendez J, Zimmerman K, Otto P, Vidugiris G, Zhu J, Darzins A, Klaubert DH, Bulleit RF, Wood KV. ACS Chem Biol. 2008;3:373–82. [PubMed]
12. Keppler A, Pick H, Arrivoli C, Vogel H, Johnsson K. Proc Natl Acad Sci U S A. 2004;101:9955–9. [PubMed]
13. Marks KM, Braun PD, Nolan GP. Proc Natl Acad Sci U S A. 2004;101:9982–7. [PubMed]
14. Calloway NT, Choob M, Sanz A, Sheetz MP, Miller LW, Cornish VW. Chembiochem. 2007;8:767–74. [PubMed]
15. Guignet EG, Hovius R, Vogel H. Nat Biotechnol. 2004;22:440–4. [PubMed]
16. Bertozzi CR. Acc Chem Res. 2011;44:651–3. [PubMed]
17. Martin BR, Giepmans BN, Adams SR, Tsien RY. Nat Biotechnol. 2005;23:1308–14. [PubMed]
18. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, Sundaresan G, Wu AM, Gambhir SS, Weiss S. Science. 2005;307:538–44. [PMC free article] [PubMed]
19. Perler FB. IUBMB Life. 2005;57:469–76. [PubMed]
20. Shi J, Muir TW. J Am Chem Soc. 2005;127:6198–206. [PubMed]
21. Kwon Y, Coleman MA, Camarero JA. Angew Chem Int Ed. 2006;45:1726–1729. [PubMed]
22. Kurpiers T, Mootz HD. Chembiochem. 2008;9:2317–25. [PubMed]
23. Dassa B, Amitai G, Caspi J, Schueler-Furman O, Pietrokovski S. Biochemistry. 2007;46:322–30. [PubMed]
24. Zettler J, Schutz V, Mootz HD. FEBS Lett. 2009;583:909–14. [PubMed]
25. Mootz HD, Blum ES, Tyszkiewicz AB, Muir TW. J Am Chem Soc. 2003;125:10561–9. [PubMed]
26. Vila-Perello M, Hori Y, Ribo M, Muir TW. Angew Chem Int Ed. 2008;47:7764–7. [PMC free article] [PubMed]
27. Berrade L, Kwon Y, Camarero JA. Chembiochem. 2010;11:1368–72. [PMC free article] [PubMed]
28. Binschik J, Zettler J, Mootz HD. Angew Chem Int Ed Engl. 2011;50:3249–52. [PubMed]
29. Evans TC, Jr, Martin D, Kolly R, Panne D, Sun L, Ghosh I, Chen L, Benner J, Liu XQ, Xu MQ. J Biol Chem. 2000;275:9091–4. [PubMed]
30. Abel-Santos E, Scott CP, Benkovic SJ. Methods Mol Biol. 2003;205:281–294. [PubMed]
31. Camarero JA, Kimura RH, Woo YH, Shekhtman A, Cantor J. Chembiochem. 2007;8:1363–6. [PubMed]
32. Austin J, Wang W, Puttamadappa S, Shekhtman A, Camarero JA. Chembiochem. 2009;10:2663–70. [PMC free article] [PubMed]
33. Girish A, Sun H, Yeo DS, Chen GY, Chua TK, Yao SQ. Bioorg Med Chem Lett. 2005;15:2447–51. [PubMed]
34. Camarero JA, Kwon Y, Coleman MA. J Am Chem Soc. 2004;126:14730–1. [PubMed]
35. Camarero JA. Biopolymers. 2008;90:450–8. [PubMed]
36. Mootz HD. Chembiochem. 2009;10:2579–89. [PubMed]
37. Camarero JA, Shektman A, Campbell E, Chlenov M, Gruber TM, Bryant DA, Darst SA, Cowburn D, Muir TW. Proc Natl Acad Sci USA. 2002;99:8536–8541. [PubMed]
38. Muralidharan V, Muir TW. Nat Methods. 2006;3:429–38. [PubMed]
39. Iwai H, Zuger S. Biotechnol Genet Eng Rev. 2007;24:129–45. [PubMed]
40. Flavell RR, Muir TW. Acc Chem Res. 2009;42:107–16. [PubMed]
41. Dhar T, Mootz HD. Chem Commun (Camb) 2011;47:3063–5. [PubMed]
42. Shah NH, Vila-Perello M, Muir TW. Angew Chem Int Ed Engl. 2011;50:6511–5. [PMC free article] [PubMed]
43. Wu H, Hu Z, Liu XQ. Proc Natl Acad Sci USA. 1998;95:9226–9231. [PubMed]
44. Wei XY, Sakr S, Li JH, Wang L, Chen WL, Zhang CC. Res Microbiol. 2006;157:227–34. [PubMed]
45. Martin DD, Xu MQ, Evans TC., Jr Biochemistry. 2001;40:1393–402. [PubMed]
46. Sun P, Ye S, Ferrandon S, Evans TC, Xu MQ, Rao Z. J Mol Biol. 2005;353:1093–105. [PubMed]
47. Iwai H, Zuger S, Jin J, Tam PH. FEBS Lett. 2006;580:1853–8. [PubMed]
48. Oeemig JS, Aranko AS, Djupsjobacka J, Heinamaki K, Iwai H. FEBS Lett. 2009;583:1451–6. [PubMed]
49. Wang CC, Chen JJ, Yang PC. Expert Opin Ther Targets. 2006;10:253–66. [PubMed]
50. Gronroos E, Terentiev AA, Punga T, Ericsson J. Proc Natl Acad Sci U S A. 2004;101:12165–70. [PubMed]
51. Sui G, Affar el B, Shi Y, Brignone C, Wall NR, Yin P, Donohoe M, Luke MP, Calvo D, Grossman SR. Cell. 2004;117:859–72. [PubMed]
52. Chariot(tm), A. M. o. N. A. h. w.;
53. Morris MC, Depollier J, Mery J, Heitz F, Divita G. Nat Biotechnol. 2001;19:1173–6. [PubMed]
54. Henriques ST, Costa J, Castanho MA. Biochemistry. 2005;44:10189–98. [PubMed]
55. Miyamoto Y, Imamoto N, Sekimoto T, Tachibana T, Seki T, Tada S, Enomoto T, Yoneda Y. J Biol Chem. 1997;272:26375–81. [PubMed]
56. Dawson PE, Muir TW, Clark-Lewis I, Kent SBH. Science. 1994;266:776–779. [PubMed]
57. Muir TW. Annu Rev Biochem. 2003;72:249–289. [PubMed]
58. Volkmann G, Iwai H. Mol Biosyst. 2010;6:2110–21. [PubMed]
59. Clamp M, Cuff J, Searle SM, Barton GJ. Bioinformatics. 2004;20:426–7. [PubMed]